Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Ruxolitinib in Myelofibrosis (Madison)
NCT02436135Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idelalisib in myelofibrosis (MF) (4 cohorts), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events at 28 days, Percentage of Participants Experiencing Adverse Events Related to Idelalisib at 28 days and 2 more. Started Jun 2015; status: terminated.
02
Drugs
idelalisib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02436135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436135.